Results 81 to 90 of about 224,706 (187)

Demographics, Initial Clinical Presentation, and Diagnostic Practices of Thyroid Eye Disease: Insights From a Pilot Survey of Oculoplastic Surgeons

open access: yesAdvances in Public Health, Volume 2026, Issue 1, 2026.
Purpose Thyroid eye disease (TED) is the most common orbital disorder in adults. Its initial clinical manifestations are heterogeneous and may influence early diagnosis and management. However, limited data exist on real‐world perspectives from oculoplastic surgeons who frequently manage patients with TED.
Shiqi Hui   +4 more
wiley   +1 more source

Surgical Treatment of Graves’ Orbitopathy

open access: yes, 2023
Abstract Surgical treatment for patients with Graves’ orbitopathy consists of orbital decompression, strabismus surgery and eyelid surgery. In this chapter, we will limit ourselves to orbital decompression (refer for strabismus surgery: Chap. 6 and for eyelid surgery: Chap.
Mourits, Maarten P.   +2 more
openaire   +2 more sources

RNFL Study in Graves Orbitopathy

open access: yes, 2010
Purpose:to determine changes of retinal nerve fiber layer (RNFL) in a group of patients with serious thyroid-related immune orbitopathy and compare it with a group of patients with moderate Graves orbitopathy.
CAMPANERUT, SARA   +4 more
core  

Alemtuzumab‐Induced Graves’ Disease Complicated by Pretibial Myxoedema: A Case Report

open access: yesCase Reports in Endocrinology, Volume 2026, Issue 1, 2026.
Background Alemtuzumab, a monoclonal antibody targeting CD52, is associated with a high incidence of secondary autoimmune disease, most commonly thyroid dysfunction. Alemtuzumab‐induced Graves’ disease (AIGD) typically follows a relapsing course and may exhibit atypical or severe phenotypes during immune reconstitution (IR). Case Presentation We report
Aongus O’Brolchain   +2 more
wiley   +1 more source

Prevention of Graves' Orbitopathy: Early Diagnosis of Thyroid-Associated Orbitopathy in Graves' Disease [PDF]

open access: yesOrbit, 2008
In spite of 200 years of research, the pathogenesis of Graves' orbitopathy (GO) remains an enigma.
openaire   +3 more sources

Graves′ orbitopathy: Management of difficult cases

open access: yesIndian Journal of Endocrinology and Metabolism, 2012
Management of Graves′ ophthalmopathy (GO) is based on three pillars: to stop smoking, to restore and maintain euthyroidism, and to treat the eye changes according to severity and activity of GO.
Wilmar M Wiersinga
doaj   +1 more source

Endoscopic Orbital Decompression for Graves’ Orbitopathy – A Vietnam Study

open access: yesClinical Ophthalmology, 2021
Thi My Hanh Pham,1,2 Chien Thang Nguyen,1 Quoc Tung Mai,2 Thi Huong Giang Bui,2 Dung Hoa Do,2 Peter McCluskey,3 Trong Van Pham2 1Department of Ophthalmology, 103 Military Hospital, Hanoi, Vietnam; 2Department of Ophthalmology, Hanoi Medical University ...
Pham TMH   +6 more
doaj  

Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement

open access: yesOrphanet Journal of Rare Diseases, 2017
Background Graves’ orbitopathy (GO) is an autoimmune condition, which is associated with poor clinical outcomes including impaired quality of life and socio-economic status.
P. Perros   +23 more
doaj   +1 more source

Novel treatment modalities for Graves' orbitopathy

open access: yes, 2010
Non-surgical treatments for moderate to severe and active Graves' orbitopathy (systemic glucocorticoids with or without orbital radiotherapy) have limited effects on the underlying autoimmune process causing the disease.
AZZOLINI, CLAUDIO   +9 more
core  

Genetic profiling of orbital fibroblasts from patients with Graves' orbitopathy

open access: yes, 2021
Graves' orbitopathy (GO) is an autoimmune disease persisting when immunosuppression is achieved. Orbital fibroblasts from GO patients display peculiar phenotypes even if not exposed to autoimmunity, possibly reflecting genetic or epigenetic mechanisms ...
Dottore, Giovanna Rotondo   +12 more
core   +1 more source

Home - About - Disclaimer - Privacy